keyword
https://read.qxmd.com/read/38634956/clinical-relevance-of-glycosylation-in-triple-negative-breast-cancer-a-review
#1
REVIEW
Mrinmoy Chakraborty, Jasmine Kaur, Gunjan, Meghavi Kathpalia, Navkiran Kaur
Glycosylation alterations in TNBC have significant implications for tumor behavior, diagnosis, prognosis, and therapeutic strategies. Dysregulated glycosylation affects cell adhesion, signaling, immune recognition, and response to therapy in TNBC. Different types of glycosylation, including N-linked glycosylation, O-linked glycosylation, glycosphingolipid glycosylation, mucin-type glycosylation, and sialylation, play distinct roles in TNBC. The "barcoding" method based on glycosylation sites of the membrane type mannose receptor (MR) shows promise in accurately distinguishing breast cancer subtypes, including TNBC...
April 18, 2024: Glycoconjugate Journal
https://read.qxmd.com/read/38634209/spatiotemporally-controlled-t-cell-combination-therapy-for-solid-tumor
#2
JOURNAL ARTICLE
Meixi Hao, Ying Zhou, Sijia Chen, Yu Jin, Xiuqi Li, Lingjing Xue, Mingxuan Shen, Weishuo Li, Can Zhang
Due to multidimensional complexity of solid tumor, development of rational T-cell combinations and corresponding formulations is still challenging. Herein, a triple combination of T cells are developed with Indoleamine 2,3-dioxygenase inhibitors (IDOi) and Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). To maximize synergism, a spatiotemporally controlled T-cell engineering technology to formulate triple drugs into one cell therapeutic, is established. Specifically, a sequentially responsive core-shell nanoparticle (SRN) encapsulating IDOi and CDK4/6i is anchored onto T cells...
April 17, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38632652/outcomes-of-sentinel-node-biopsy-according-to-mri-response-in-an-association-with-the-subtypes-in-cn1-3-breast-cancer-after-neoadjuvant-systemic-therapy-multicenter-cohort-study
#3
JOURNAL ARTICLE
Soong June Bae, Jung Whan Chun, Sae Byul Lee, Jai Min Ryu, Seok Jin Nam, Joon Jeong, Hyung Seok Park, Sung Gwe Ahn
BACKGROUND: This study investigated the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) in patients with initially high nodal burden. METHODS: In the multicenter retrospective cohort, 388 individuals with cN1-3 breast cancer who underwent NAST and had SLNB followed by completion axillary lymph node dissection were included. In an external validation cohort, 267 patients with HER2+ or triple-negative breast cancer (TNBC) meeting similar inclusion criteria were included...
April 17, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38632570/characterising-smoking-and-nicotine-use-behaviours-among-women-of-reproductive-age-a-10-year-population-study-in-england
#4
JOURNAL ARTICLE
Sarah E Jackson, Jamie Brown, Caitlin Notley, Lion Shahab, Sharon Cox
BACKGROUND: Tobacco smoking affects women's fertility and is associated with substantial risks of adverse pregnancy outcomes. This study explored trends by socioeconomic position in patterns of smoking, use of non-combustible nicotine products, and quitting activity among women of reproductive age in England. METHODS: Data come from a nationally representative monthly cross-sectional survey. Between October 2013 and October 2023, 197,266 adults (≥ 18 years) were surveyed, of whom 44,052 were women of reproductive age (18-45 years)...
April 18, 2024: BMC Medicine
https://read.qxmd.com/read/38631620/effect-of-canal-medicaments-triple-antibiotic-paste-bio-c-temp-and-nano-silver-gel-activated-by-visible-blue-light-on-canal-dentin-microhardness-and-extrusion-bond-strength-of-ah-plus-sealer-a-sem-and-edx-analysis
#5
JOURNAL ARTICLE
Laila AlDeeb, Thamer Almohareb, Khold Alahdal, Ahmed Maawadh, Ahoud S Alshamrani, Ali Alrahlah
Assessment of contemporary canal medicaments (Triple antibiotic paste (TAP), Bio-C Temp, and Nano silver gel activated by visible blue light on the dentin microhardness (MH) and push-out bond strength (PBS) of AH plus endodontic sealer METHOD: : Sixty extracted premolars were obtained and decontaminated. Canal cleaning and shaping were performed. The samples were randomly allocated into four groups based on the intracanal medicaments. Group 1= CH paste, Group 2= TAP, Group 3= Bio-C Temp, and Group 4= Nano-silver gel activated by visible blue light...
April 15, 2024: Photodiagnosis and Photodynamic Therapy
https://read.qxmd.com/read/38630392/pi3k-akt-mtor-signaling-pathway-an-important-driver-and-therapeutic-target-in-triple-negative-breast-cancer
#6
REVIEW
Huan-Ping Zhang, Rui-Yuan Jiang, Jia-Yu Zhu, Ke-Na Sun, Yuan Huang, Huan-Huan Zhou, Ya-Bing Zheng, Xiao-Jia Wang
Triple-negative breast cancer (TNBC) is a highly heterogeneous tumor lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. It has higher aggressiveness and metastasis than other subtypes, with limited effective therapeutic strategies, leading to a poor prognosis. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway is prevalently over-activated in human cancers and contributes to breast cancer (BC) growth, survival, proliferation, and angiogenesis, which could be an interesting therapeutic target...
April 17, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://read.qxmd.com/read/38630386/improved-outcomes-for-triple-negative-breast-cancer-brain-metastases-patients-after-stereotactic-radiosurgery-and-new-systemic-approaches
#7
JOURNAL ARTICLE
Elad Mashiach, Juan Diego Alzate, Fernando De Nigris Vasconcellos, Sylvia Adams, Brandon Santhumayor, Ying Meng, Zane Schnurman, Bernadine R Donahue, Kenneth Bernstein, Cordelia Orillac, Rishitha Bollam, Maryann J Kwa, Marleen Meyers, Ruth Oratz, Yelena Novik, Joshua S Silverman, David H Harter, John G Golfinos, Douglas Kondziolka
PURPOSE: Although ongoing studies are assessing the efficacy of new systemic therapies for patients with triple negative breast cancer (TNBC), the overwhelming majority have excluded patients with brain metastases (BM). Therefore, we aim to characterize systemic therapies and outcomes in a cohort of patients with TNBC and BM managed with stereotactic radiosurgery (SRS) and delineate predictors of increased survival. METHODS: We used our prospective patient registry to evaluate data from 2012 to 2023...
April 17, 2024: Journal of Neuro-oncology
https://read.qxmd.com/read/38629963/maintenance-pembrolizumab-therapy-in-patients-with-metastatic-her2-negative-breast-cancer-with-prior-response-to-chemotherapy
#8
JOURNAL ARTICLE
Toshiaki Iwase, Evan N Cohen, Hui Gao, Angela Alexander, Megumi Kai, Vivian Chiv, Xiaoping Wang, Savitri Krishnamurthy, Diane Liu, Yu Shen, Kumiko Kida, Alexandre Reuben, Rachel Layman, David Ramirez, Debu Tripathy, Stacy L Moulder, Clinton Yam, Vicente Valero, Bora Lim, James M Reuben, Naoto T Ueno
PURPOSE: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy of maintenance immunotherapy in patients with metastatic HER2-negative inflammatory breast cancer (IBC) and non-IBC triple-negative breast cancer (TNBC) and a biomarker study. PATIENTS AND METHODS: Patients with a complete response (CR), partial response (PR), or stable disease (SD) after at least 3 cycles of chemotherapy for HER2-negative breast cancer received pembrolizumab, regardless of programmed death-ligand 1 expression...
April 17, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38628818/does-the-dose-of-standard-adjuvant-chemotherapy-affect-the-triple-negative-breast-cancer-benefit-from-extended-capecitabine-metronomic-therapy-an-exploratory-analysis-of-the-sysucc-001-trial
#9
Ying Chen, Wen-Xia Li, Jia-Hua Wu, Geng-Hang Chen, Chun-Min Yang, Hai Lu, Xi Wang, Shu-Sen Wang, Heng Huang, Li Cai, Li Zhao, Rou-Jun Peng, Ying Lin, Jun Tang, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, An-Qin Zhang, Fei Xu, Xi-Wen Bi, Jia-Jia Huang, Ji-Bin Li, Dan-Mei Pang, Cong Xue, Yan-Xia Shi, Zhen-Yu He, Huan-Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Ruo-Xi Hong, Kui-Kui Jiang, Yong-Yi Zhong, Ge Zhang, Piyawan Tienchaiananda, Masahiro Oikawa, Zhong-Yu Yuan, Qian-Jun Chen
PURPOSE: Results from studies of extended capecitabine after the standard adjuvant chemotherapy in early stage triple-negative breast cancer (TNBC) were inconsistent, and only low-dose capecitabine from the SYSUCC-001 trial improved disease-free survival (DFS). Adjustment of the conventional adjuvant chemotherapy doses affect the prognosis and may affect the efficacy of subsequent treatments. This study investigated whether the survival benefit of the SYSUCC-001 trial was affected by dose adjustment of the standard adjuvant chemotherapy or not...
2024: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/38627804/beta-blockers-or-placebo-for-primary-prophylaxis-boppp-of-oesophageal-varices-study-protocol-for-a-randomised-controlled-trial
#10
JOURNAL ARTICLE
Vishal C Patel, Mark J McPhail, Ruhama Uddin, Hassan Jafari, Vanessa Lawrence, Clair Le Boutillier, James Shearer, Nahel Yaziji, Angela Cape, Haroon Ahmed, Christopher Ward, Peter Walsh, Kevin Besly, Ane Zamalloa, Joanna Kelly, Ben Carter
BACKGROUND: Liver disease is within the top five causes of premature death in adults. Deaths caused by complications of cirrhosis continue to rise, whilst deaths related to other non-liver disease areas are declining. Portal hypertension is the primary sequelae of cirrhosis and is associated with the development of variceal haemorrhage, ascites, hepatic encephalopathy and infection, collectively termed hepatic decompensation, which leads to hospitalisation and mortality. It remains uncertain whether administering a non-selective beta-blocker (NSBB), specifically carvedilol, at an earlier stage, i...
April 16, 2024: Trials
https://read.qxmd.com/read/38627334/evaluation-of-chemotherapy-induced-nausea-and-vomiting-in-pediatric-patients-with-high-grade-glioma-treated-with-lomustine-a-case-series
#11
JOURNAL ARTICLE
Kim P J Schellekens, Sarah Babette Hageman, Els C Haverkate, Marianne D van de Wetering, Frederike K Engels, Aeltsje Brinksma, Evelien de Vos-Kerkhof
PURPOSE: Although lomustine has been used as a chemotherapeutic agent for decades, no recommendation on appropriate chemotherapy-induced nausea and vomiting (CINV) prophylaxis is available. As CINV is considered one of the most bothersome side effects of chemotherapy, adequate prophylaxis is of relevance to improve quality of life during cancer treatment. The aim of this retrospective case series was to report the incidence and severity of CINV in pediatric patients with high-grade glioma treated with lomustine and to formulate recommendations for appropriate CINV prophylaxis...
April 16, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38626972/cardiovascular-safety-of-evogliptin-dual-and-triple-therapy-in-patients-with-type-2-diabetes-a-nationwide-cohort-study
#12
JOURNAL ARTICLE
Sohee Park, Han Eol Jeong, In-Sun Oh, Sangmo Hong, Sung Hoon Yu, Chang Beom Lee, Ju-Young Shin
OBJECTIVE: To investigate the risk of cardiovascular events associated with commonly used dual and triple therapies of evogliptin, a recently introduced dipeptidyl peptidase-4 inhibitor (DPP4i), for managing type 2 diabetes in routine clinical practice. DESIGN: A retrospective cohort study. SETTING: Korean Health Insurance Review and Assessment database. PARTICIPANTS: Patients who initiated metformin-based dual therapy and metformin+sulfonylurea-based triple therapy in South Korea from 2014 to 2018...
April 15, 2024: BMJ Open
https://read.qxmd.com/read/38626371/optimizing-pharmacotherapy-management-of-copd-don-t-miss-the-forest-for-the-trees
#13
JOURNAL ARTICLE
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Erika Penz, Darcy D Marciniuk
No abstract text is available yet for this article.
April 16, 2024: American Journal of Respiratory and Critical Care Medicine
https://read.qxmd.com/read/38623967/role-of-%C3%AE-3-subunit-of-the-gaba-type-a-receptor-in-triple-negative-breast-cancer-proliferation-migration-and-cell-cycle-progression
#14
JOURNAL ARTICLE
J Bundy, J Shaw, M Hammel, J Nguyen, C Robbins, I Mercier, A Suryanarayanan
Triple negative breast cancer (TNBC) is known for its heterogeneous nature and aggressive onset. The unresponsiveness to hormone therapies and immunotherapy and the toxicity of chemotherapeutics account for the limited treatment options for TNBC. Ion channels have emerged as possible therapeutic candidates for cancer therapy, but little is known about how ligand gated ion channels, specifically, GABA type A ligand-gated ion channel receptors (GABAA R), affect cancer pathogenesis. Our results show that the GABAA β3 subunit is expressed at higher levels in TNBC cell lines than non-tumorigenic cells, therefore contributing to the idea that limiting the GABAA R via knockdown of the GABAA β3 subunit is a potential strategy for decreasing the proliferation and migration of TNBC cells...
April 16, 2024: Cell Cycle
https://read.qxmd.com/read/38623474/testing-for-the-lupus-anticoagulant-the-good-the-bad-and-the-ugly
#15
JOURNAL ARTICLE
Emmanuel J Favaloro, Leonardo Pasalic, Rita Selby
Lupus anticoagulant (LA) represents 1 of the laboratory criteria for classification of patients as having definite antiphospholipid syndrome (APS). The other 2 laboratory criteria are anticardiolipin antibodies and anti-beta2-glycoprotein I antibodies. At least 1 of these antiphospholipid antibody (aPL) tests need to be positive, with evidence of persistence, together with evidence of at least 1 clinical criterion for APS, before a patient can be classified as having definite APS. LA and other aPL assays are also important for diagnosis or exclusion of APS, as well as for risk stratification, with triple-positive patients carrying the greatest risk...
March 2024: Research and Practice in Thrombosis and Haemostasis
https://read.qxmd.com/read/38623144/real-world-data-on-treatment-patterns-in-at-least-high-cardiovascular-risk-patients-on-dual-and-triple-lipid-lowering-therapy-in-a-hellenic-nationwide-e-prescription-database
#16
JOURNAL ARTICLE
Dimitrios Terentes-Printzios, Ioanna Dima, Panorios Benardos, Panagiota Mitrou, Konstantinos Mathioudakis, Anastasios Tsolakidis, Fotios Barkas, Konstantinos Tsioufis, Petros P Sfikakis, Evangelos Liberopoulos, Charalambos Vlachopoulos
BACKGROUND: Despite recent guidelines appropriate lipid-lowering treatment (LLT) remains suboptimal in everyday clinical practice. AIMS: We aimed to describe clinical practice of use of LLT for at least high CV risk populations in a Hellenic real-world setting and assess how this relates to the European Society of Cardiology treatment guidelines. METHODS: We analyzed data from a retrospective cohort study of the National Registry of patients with dyslipidemia between 1/7/2017 and 30/6/2019 who were at least of high CV risk and filled a dual or triple lipid-lowering treatment (dLLT, tLLT) prescription...
June 2024: Int J Cardiol Cardiovasc Risk Prev
https://read.qxmd.com/read/38622760/coiled-coil-protein-hydrogels-engineered-with-minimized-fiber-diameters-for-sustained-release-of-doxorubicin-in-triple-negative-breast-cancer
#17
JOURNAL ARTICLE
Dustin Britton, Jakub Legocki, Deven Paul, Olga Katsara, Orlando Aristizabal, Neelam Pandya, Orin Mishkit, Yingxin Xiao, Matias Aristizabal, Neha Rahman, Robert Schneider, Youssef Z Wadghiri, Jin Kim Montclare
Triple-negative breast cancer (TNBC) lacks expressed protein targets, making therapy development challenging. Hydrogels offer a promising new route in this regard by improving the chemotherapeutic efficacy through increased solubility and sustained release. Moreover, subcutaneous hydrogel administration reduces patient burden by requiring less therapy and shorter treatment times. We recently established the design principles for the supramolecular assembly of single-domain coiled-coils into hydrogels. Using a modified computational design algorithm, we designed Q8, a hydrogel with rapid assembly for faster therapeutic hydrogel preparation...
April 15, 2024: ACS Biomaterials Science & Engineering
https://read.qxmd.com/read/38622359/community-cohesion-looseness-in-gene-networks-reveals-individualized-drug-targets-and-resistance
#18
JOURNAL ARTICLE
Seunghyun Wang, Doheon Lee
Community cohesion plays a critical role in the determination of an individual's health in social science. Intriguingly, a community structure of gene networks indicates that the concept of community cohesion could be applied between the genes as well to overcome the limitations of single gene-based biomarkers for precision oncology. Here, we develop community cohesion scores which precisely quantify the community ability to retain the interactions between the genes and their cellular functions in each individualized gene network...
March 27, 2024: Briefings in Bioinformatics
https://read.qxmd.com/read/38621608/impact-of-radiation-therapy-modalities-on-loco-regional-control-in-inflammatory-breast-cancer
#19
JOURNAL ARTICLE
Maximilien Rogé, Youlia Kirova, Emilie Lévêque, Marin Guigo, Alison Johnson, Rafik Nebbache, Eleonor Rivin Del Campo, Ioana Lazarescu, Stéphanie Servagi, Augustin Mervoyer, Axel Cailleteau, Sébastien Thureau, Juliette Thariat
INTRODUCTION: In inflammatory breast cancer (IBC), radiotherapy intensification is considered a standard of care by some teams, although the level of evidence remains low. We sought to analyze the impact of radiotherapy modalities on the risk of loco-regional and distant relapse. METHODS: A retrospective multicenter study included patients with localized IBC treated between 2010 and 2017. Standard post-mastectomy radiotherapy consisted of daily fractions to a total dose of 50 Gy equivalent without a boost or bolus, while intensified radiotherapy referred to the use of a boost or bolus...
April 13, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38621548/cost-effectiveness-analysis-of-fluticasone-furoate-umeclidinium-bromide-vilanterol-and-umeclidinium-bromide-vilanterol-in-the-management-of-moderate-and-severe-copd-in-china
#20
JOURNAL ARTICLE
Yuan Zhou, Shujing Duan, Lei Zhang, Fangchen Peng
OBJECTIVE: A study has analyzed the long-term cost-effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol combination therapy (FF/UMEC/VI) versus umeclidinium bromide/vilanterol dual therapy (UMEC/VI) in the treatment of moderate or severe chronic obstructive pulmonary disease (COPD), providing evidence for decision-making in COPD treatment. METHODS: From the perspective of the whole society, a Markov model based on the severity of COPD was established, consisting of four states: moderate, severe, very severe, and death ...
April 13, 2024: Respiratory Medicine
keyword
keyword
46865
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.